Trial Profile
A pilot study for the efficacy of the non-benzodiazepine hypnotic or orexin receptor antagonist on insomnia in major depressive patients unresponsive to benzodiazepine hypnotic treatment: a randomized open-label trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Eszopiclone (Primary) ; Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 01 May 2022 Results assessing the the utility of switching from benzodiazepines to suvorexant or eszopiclone to manage benzodiazepine-unresponsive insomnia in patients with major depressive disorder published in the Clinical Neuropharmacology
- 28 Jun 2020 Status changed from recruiting to completed.
- 27 Mar 2018 Status changed from not yet recruiting to recruiting.